Zobrazeno 1 - 10
of 770
pro vyhledávání: '"Caro, A."'
Autor:
Davide Costabile, Giulia De Riso, Paolo Cappabianca, Stephan Frank, Salvatore Tafuto, Alessandro Ottaiano, Annabella Di Mauro, Roberto Tafuto, Rosa Della Monica, Lorenzo Chiariotti, Roberta Visconti, Sabrina Lamia, Fabiana Tatangelo, Marialaura Del Basso De Caro, Juergen Hench, Michela Buonaiuto, Mariella Cuomo, Elia Guadagno, Teodolinda Di Risi
Publikováno v:
Oncology Research
Unresectable neuroendocrine neoplasms (NENs) often poorly respond to standard therapeutic approaches. Alkylating agents, in particular temozolomide, commonly used to treat high-grade brain tumors including glioblastomas, have recently been tested in
Publikováno v:
Archivos de la Sociedad Española de Oftalmología (English Edition). 96:602-606
Idiopathic macular telangiectasia type 1 (MacTel 1) almost always occurs unilaterally. In this article, we report the case of a 73-year-old man with no significant history diagnosed with MacTel 1 but with atypical bilateral presentation, something ve
Publikováno v:
Archivos de la Sociedad Española de Oftalmología (English Edition). 96:434-437
Paclitaxel is used to treat a wide range of malignant tumours. This type of drug is known to cause ocular adverse effects, with cystoid macular oedema being a known, but rare complication, of this therapy. Although most cases resolve after discontinu
Publikováno v:
American Society of Clinical Oncology Educational Book. :291-309
Survival in multiple myeloma has improved greatly during the past 2 decades, but this change has primarily benefited patients who have standard-risk disease. Patients with high-risk disease remain a challenge to diagnose and treat. To improve their c
Autor:
Luna Musib, Josina C. Reddy, Sravanthi Cheeti, Sandhya Girish, Jin Y. Jin, Pascal Chanu, Rene Bruno, Tong Lu, Ivor Caro, Xin Wang
Publikováno v:
Journal of Investigative Dermatology. 141:930-933
Summary Long-term use of vismodegib is associated with treatment-emergent adverse drug reactions in clinical trials of patients with locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC). Treatment interruptions have been recommende
Autor:
Bertolini, F., Ostuzzi, G., Pievani, M., Aguglia, A., Bartoli, F., Bortolaso, P., Callegari, C., Caroleo, M., Carra, G., Corbo, M., D'Agostino, A., De Fazio, P., Magliocco, F., Martinotti, G., Ostinelli, E. G., Piccinelli, M. P., Tedeschi, F., Barbui, C., Boschello, F., Gastaldon, C., Mazzi, M. A., Nose, M., Papola, D., Perini, G., Piccoli, A., Purgato, M., Ruggeri, M., Terlizzi, S., Turrini, G., Raffaele, G., Cavallotti, S., Chirico, M., Ferrato, F., Limosani, I., Mastromo, D., Monzani, E., Porcellana, M., Restaino, F., Annese, P. M., Bolognesi, S., Cerretini, M., De Capua, A., Debolini, S., Del Zanna, M., Fargnoli, F., Giannini, A., Luccarelli, L., Lucii, C., Pierantozzi, E., Tozzi, F., Bardicchia, F., Cardamone, G., Facchi, E., Magnani, N., Soscia, F., Biancosino, B., Zotos, S., Giacomin, M., Pompei, F., Spano, M., Zonta, F., Buzzi, A., Callegred, C., Calzolari, R., Caselli, I., Diurni, M., Giana, E., Ielmini, M., Milano, A., Poloni, N., Sani, E., Zizolfi, D., Alberini, G., Cazzamalli, S., Costantini, C., Di Caro, A., Paronelli, C., Piantanida, S., Piccinelli, M., Alessandro, P., Barbanti, S. V., D'Ippolito, C., Gozzi, M., Moretti, V., Campese, O., Di Capro, L., di Giannantonio, M., Fiori, F., Lorusso, M., Mancini, V., Viceconte, D., Calandra, C., Luca, M., Signorelli, M. S., Suraniti, F., Balzarro, B., Boncompagni, G., Caretto, V., Emiliani, R., Lupoli, P., Menchetti, M., Rossi, E., Storbini, V., Tarricone, I., Terzi, L., Boso, M., Catania, C., De Paoli, G., Risaro, P., Aspesi, F., Bava, M., Bono, A., Brambilla, G., Castagna, G., Lucchi, S., Nava, R., Provenzi, M., Tabacchi, T., Tremolada, M., Verrengia, E., Barchiesi, M., Oriani, M. G., Pacetti, M., Ferro, M., Ghio, L., Beneduce, R., Laffranchini, L., Magni, L. R., Rossi, G., Tura, G. B., Addeo, L., Balletta, G., De Vivo, E., Di Benedetto, R., Parise, V. F., Carpiniello, B., Pinna, F., Pecile, D., Mattei, C., Bonavigo, T., Fabrici, E. P., Panarello, S., Peresson, G., Vitucci, C., Gardellin, F., Strizzolo, S., Cossetta, E., Fizzotti, C., Moretti, D., Di Gregorio, L., Sozzi, F., Colli, G., La Barbera, D., Laurenzi, S.
Publikováno v:
CNS Drugs
Background Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fe68adbd371a958c009ab69f34cb011
http://hdl.handle.net/11567/1057042
http://hdl.handle.net/11567/1057042
Autor:
Andrea Sechi, A. Offidani, Marina Venturini, Piergiacomo Calzavara-Pinton, Andrea Chiricozzi, Eleonora Candi, Ketty Peris, Raffaele Dante Caposiena Caro, Clara De Simone, Annalisa Patrizi, E. Molinelli, Luca Bianchi
Publikováno v:
Italian Journal of Dermatology and Venereology. 157
Background Hidradenitis suppurativa (HS) is characterized by periodic worsening of symptoms. However, clinical parameters associated with flare are still to be established. The aim was too investigate factors associated with flare outbreak in HS pati
Autor:
Christine Fandozzi, Deborah Panebianco, Luzelena Caro, Dennis Wolford, Zifang Guo, Iain P. Fraser, Dennis Swearingen, Vanessa Levine, Hwa-Ping Feng, Thomayant Prueksaritanont, Joan R. Butterton, Marian Iwamoto, Wendy W. Yeh
Publikováno v:
Clinical Drug Investigation. 41:133-147
Many people infected with hepatitis C virus have comorbidities, including hypercholesterolemia, that are treated with statins. In this study, we evaluated the drug–drug interaction potential of the hepatitis C virus inhibitors elbasvir (EBR) and gr
Publikováno v:
American Journal of Nephrology. 52:435-449
Background: Although diuretics are one of the most widely used drugs by nephrologists, their antiproteinuric properties are not generally taken into consideration. Summary: Thiazide diuretics have been shown to reduce proteinuria by >35% in several p
Autor:
Margarita Majem, Bartomeu Massuti, Joaquim Bosch-Barrera, Ana Drozdowskyj, Pilar Lianes, Delvys Rodriguez-Abreu, Miguel Angel Molina-Vila, M. Guirado, David Vicente, Sergio Vazquez-Estevez, A. Insa, Niki Karachaliou, Manuel Domine, Rafael Rosell, Rosario García-Campelo, Reyes Bernabe Caro, Oscar Arrieta, María Ángeles Sala, Ana Verdu, Ana Laura Ortega Granados, Noemi Reguart
Publikováno v:
Lung Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Objectives Progression-free survival (PFS) and response rate to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung cancer (NSCLC) driven byEGFR mutations, suggesting that other geneti